AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 623-632

  Zekri, Ali ^a   Ghaffari, Seyed H ^b   Ghanizadeh Vesali, Samad ^b   Yaghmaie, Marjan ^b   Salmaninejad, Arash ^a   Alimoghaddam, Kamran ^b   Modarressi, Mohammad H ^a   Ghavamzadeh, Ardeshir ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Androgen receptor; Apoptosis; Aurora B kinase; Prostate cancer; Weak positive correlations

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; AZD 1152 HQPA; UNCLASSIFIED DRUG; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; ANEUGEN; AURKB PROTEIN, HUMAN; AURORA B KINASE; ORGANOPHOSPHATE; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LNCAP CELL LINE; MAJOR CLINICAL STUDY; MALE; MICRONUCLEUS; POLYPLOIDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANEUGENS; ANIMALS; APOPTOSIS; AURORA KINASE B; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; ORGANOPHOSPHATES; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTORS, ANDROGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925493680     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2664-8     Document Type: Article

References (37)

1. Cotton P. Case for prostate therapy wanes despite more treatment options. JAMA. 1991;266(4):459–60.
2. Greenlee RT et al. Cancer statistics, 2000. CA Cancer J Clin. 2000;50(1):7–33.
3. Jemal A et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
4. Loblaw DA et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605.
5. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25(2):276–308.
6. Pagliarulo V et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012;61(1):11–25.
7. Henshall SM et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001;61(2):423–7.
8. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34–45.
9. Hsu JY et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell. 2000;102(3):279–91.
10. Bischoff JR et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. Embo J. 1998;17(11):3052–65.
11. Lee EC et al. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res. 2006;66(10):4996–5002.
12. Li D et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res. 2003;9(3):991–7.
13. Wilkinson RW et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007;13(12):3682–8.
14. Mortlock AA et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem. 2007;50(9):2213–24.
15. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205–19.
16. Taylor WR et al. Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell. 1999;10(11):3607–22.
17. Boss DS et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011;22(2):431–7.
18. Dennis M et al. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(3):461–9.
19. Schwartz GK et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs. 2012;31(2):370–80. doi:10.1007/s10637-012-9825-7.
20. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8.
21. Niermann KJ et al. Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition. Radiat Res. 2011;175(4):444–51.
22. Yang J et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007;110(6):2034–40.
23. Gully CP et al. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer. 2010;9:42.
24. Stokes MP et al. Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci U S A. 2007;104(50):19855–60.
25. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer. 2002;2(8):605–15.
26. Stros M et al. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem. 2002;277(9):7157–64.
27. Macleod KF et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995;9(8):935–44.
28. Mirzayans R et al. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J BioMed Biotechnol. 2012;2012:170325.
29. Godfrey B et al. Proteasomal degradation unleashes the pro-death activity of androgen receptor. Cell Res. 2010;20(10):1138–47.
30. Frezza M, Yang H, Dou QP. Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli. J Cell Physiol. 2011;226(11):2731–9.
31. Lu S et al. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol. 1999;13(3):376–84.
32. Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 1997;57(20):4511–6.
33. Lilly MA, Duronio RJ. New insights into cell cycle control from the Drosophila endocycle. Oncogene. 2005;24(17):2765–75.
34. Zhong W et al. CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing. Nature. 2003;423(6942):885–9.
35. Nagata Y, Muro Y, Todokoro K. Thrombopoietin-induced polyploidization of bone marrow megakaryocytes is due to a unique regulatory mechanism in late mitosis. J Cell Biol. 1997;139(2):449–57.
36. Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev. 2009;61(1):14–25.
37. Marchetti S et al. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Investig New Drugs. 2013;31(5):1125–35.